Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Heekyong R. Bae, Patrick S.C. Leung, Koichi Tsuneyama, Julio C. Valencia, Deborah L. Hodge, Seohyun Kim, Tim Back, Megan Karwan, Anand S. Merchant, Nobuyuki Baba, Dechun Feng, Ogyi Park, Bin Gao, Guo‐Xiang Yang, M. Eric Gershwin, Howard A. Young – 14 May 2016 – In most autoimmune diseases the serologic hallmarks of disease precede clinical pathology by years. Therefore, the use of animal models in defining early disease events becomes critical.

Lee J. Hewett, Marques L. Bradshaw, Leonie L. Gordon, Don C. Rockey – 14 May 2016

Sandra Rebouissou, Andrea Franconi, Julien Calderaro, Eric Letouzé, Sandrine Imbeaud, Camilla Pilati, Jean‐Charles Nault, Gabrielle Couchy, Alexis Laurent, Charles Balabaud, Paulette Bioulac‐Sage, Jessica Zucman‐Rossi – 14 May 2016 – CTNNB1 mutations activating ß‐catenin are frequent somatic events in hepatocellular carcinoma (HCC) and adenoma (HCA), particularly associated with a risk of malignant transformation. We aimed to understand the relationship between CTNNB1 mutation types, tumor phenotype, and level of ß‐catenin activation in malignant transformation.

Dan Li, Jing Fu, Min Du, Haibin Zhang, Lu Li, Jin Cen, Weiyun Li, Xiaotao Chen, Yunfei Lin, Edward M. Conway, Eli Pikarsky, Hongyan Wang, Guoyu Pan, Yuan Ji, Hong‐Yang Wang, Lijian Hui – 14 May 2016 – Hepatocellular carcinoma (HCC) is a cancer lacking effective therapies. Several measures have been proposed to treat HCCs, such as senescence induction, mitotic inhibition, and cell death promotion. However, data from other cancers suggest that single use of these approaches may not be effective.

Lee J. Hewett, Marques L. Bradshaw, Leonie L. Gordon, Don C. Rockey – 14 May 2016

Zhi Yi Wan, Johann Shane Tian, Hayden Weng Siong Tan, Ai Lee Chow, Arthur Yi Loong Sim, Kenneth Hon Kim Ban, Yun Chau Long – 14 May 2016 – Fibroblast growth factor 19 (FGF19) is an important postprandial enterokine which regulates liver metabolism and hepatocyte proliferation. However, the precise mechanism by which FGF19 regulates these cellular effects is poorly understood. Given that mechanistic target of rapamycin complex 1 (mTORC1) regulates numerous postprandial adaptations, we investigated the potential role of mTORC1 in FGF19 action.

Michael H. Nathanson, Norah Terrault – 14 May 2016

Gonzalo Sapisochin, Nicolas Goldaracena, Jerome M. Laurence, Martin Dib, Andrew Barbas, Anand Ghanekar, Sean P. Cleary, Les Lilly, Mark S. Cattral, Max Marquez, Markus Selzner, Eberhard Renner, Nazia Selzner, Ian D. McGilvray, Paul D. Greig, David R. Grant – 14 May 2016 – The selection of liver transplant candidates with hepatocellular carcinoma (HCC) relies mostly on tumor size and number. Instead of relying on these factors, we used poor tumor differentiation and cancer‐related symptoms to exclude patients likely to have advanced HCC with aggressive biology.